# US 11,998,570 B2 · Mammalian lung spheroids and lung spheroid cells and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,998,570 B2
- Document ID: US11998570B2
- Status: Granted
- Kind: B2
- Application number: 17/071,303
- Filed: 2020-10-15
- Published: 2021-04-08
- Granted: 2024-06-04
- Earliest claimed: 2014-09-18
- Assignees: North Carolina State University
- Applicants: North Carolina State University
- Inventors: Ke Cheng; Eric T. Henry; Jhon Cores
- Web page: https://patentgrep.com/patent/US11998570B2

## CPC

- A61K 35/42: Respiratory system, e.g. lungs, bronchi or lung cells
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- C12N 5/0688: {Cells from the lungs or the respiratory tract}
- C12N 2513/00: 3D culture
- C12N 2533/50: Proteins
- C12N 2533/52: Fibronectin; Laminin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Using lung tissues as a source, mammalian lung progenitor cells lung spheroids and lung spheroid cells (LSCs) were prepared. In one embodiment mammalian LSCs were prepared by (i) culturing mammalian lung tissue explant cells under adherent culture conditions to form a first lung cell outgrowth culture; (ii) culturing the first lung cell outgrowth culture under low-adherence conditions to form lung spheroids; and (iii) culturing the lung spheroids under adherent culture conditions so as to form LSCs. The low-adherence conditions may be a cell culture or suspension. The lung spheroids or LSCs may be formulated into pharmaceutical compositions. Uses such as treatment of lung diseases or diagnostics are also provided. Lung spheroids and LSCs represents a simple and highly reproducible method to generate therapeutic lung cells.

## Claims

### Claim 1

A composition comprising a plurality of lung spheroids derived from a lung tissue explant, wherein the plurality of lung spheroids comprise:
(i) at least one lung progenitor cell;
(ii) at least one supporting stroma-like cell; and
(iii) at least one lung spheroid cell (LSC) that co-expresses at least one supporting stroma-like cell marker and at least one lung progenitor marker;
wherein the at least one progenitor cell, the at least one supporting stroma-like cell, and the at least one LSC are derived from the same lung tissue explant.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the plurality of lung spheroids are are obtained from lung tissue explants that are cultured under low-adherent conditions.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the at least one lung progenitor cell expresses one or more of Pro-Surfactant Protein C (SPC), Clara Cell Secretory Protein (CCSP), Integrin Subunit Alpha 6 (ITGA6 or CD49f), p75 Nerve Growth Factor (NGF), Epithelial Cell Adhesion Molecule (EpCAM), p63, Keratin 5 (KRT5), or any combination thereof.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the at least one LSC does not express one or more of CD45, CD31, CD34, c-kit or any combination thereof.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the at least one lung progenitor cell expresses one or more upregulated genes selected from the group consisting of Bone Morphogenetic Protein 2 (BMP2), Stromal Cell-Derived Factor 1, Fibroblast Growth Factor 2 (FGF2), or any combination thereof.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the one or more upregulated genes are upregulated as compared to pulmonary alveolar epithelial cells, dermal fibroblasts, or mesenchymal stem cells.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the at least one supporting stroma-like cell expresses express one or more of CD105, CD90, or a combination thereof.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the lung spheroids comprise diameters ranging from about 25 μm to about 500 μm.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the at least one LSC secretes one or more pro-angiogenetic factors.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the one or more pro-angiogenic factors are selected from the group consisting of insulin-like growth factor binding protein 2 (IGFBP2), hepatocyte growth factor (HGF), brain-derived neurotrophic factor (BDNF), and any combination thereof.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the at least one lung progenitor cell marker comprises Pro-Surfactant Protein C (SPC), Clara Cell Secretory Protein (CCSP), Integrin Subunit Alpha 6 (ITGA6 or CD49f), p75 Nerve Growth Factor (NGF), Epithelial Cell Adhesion Molecule (EpCAM), p63, Keratin 5 (KRT5), and Aquaporin 5 (Aq5), or any combination thereof.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the at least one supporting stroma-like cell marker comprises CD105 and/or CD90.